Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep;40(9):3956-3970.
doi: 10.1007/s12325-023-02580-4. Epub 2023 Jul 1.

Factors That Predict a Sustained Humoral Response to COVID-19 Vaccines in Kidney Transplant Recipients

Pierre Pommerolle  1 , Pierre Laurent  2 , Claire Presne  2 , François Brazier  2 , Maïté Jaureguy  2 , Coralie Poulain  2 , Gauthier Flahaut  2 , Hakim Mazouz  2 , Etienne Brochot  3 , Gabriel Choukroun  2 , Ophélie Fourdinier  2
Affiliations

Factors That Predict a Sustained Humoral Response to COVID-19 Vaccines in Kidney Transplant Recipients

Pierre Pommerolle et al. Adv Ther. 2023 Sep.

Abstract

Introduction: Kidney transplant recipients (KTRs) produce a weak humoral response to coronavirus disease 2019 (COVID-19) vaccines. However, the factors associated with the quality of the serological response to three doses of COVID-19 vaccine have not been unambiguously identified.

Methods: We included KTRs followed in the Nephrology Department at Amiens University Hospital (Amiens, France) between June and December 2021 who had received three doses of a COVID-19 mRNA vaccine (or two doses plus an episode of polymerase chain reaction-confirmed COVID-19). The lack of a humoral response was defined as an antibody titer below 7.1 binding antibody units (BAU)/mL, and an optimal response was defined as an antibody titer above 264 BAU/mL.

Results: Of the 371 patients included, 246 (66.3%) were seropositive, and 97 (26.1%) had an optimal response. In a multivariate analysis, the only factor associated with seropositivity was a history of COVID-19 [odds ratio (OR) 87.2; 95% confidence interval (CI) (7.88-965.0); p < 0.0001], while the main factors associated with non-response were female sex [OR 0.28; 95%CI (0.15-0.51); p < 0.0001], less than 36 months between kidney transplantation and vaccination [OR 0.26; 95%CI (0.13-0.52); p < 0.0001], a higher creatinine level [OR 0.33; 95%CI (0.19-0.56); p < 0.0001], the use of tacrolimus [OR 0.23; 95%CI (0.12-0.45); p < 0.0001], the use of belatacept [OR 0.01; 95%CI (0.001-0.20); p = 0.002] and three-drug immunosuppression [OR 0.39; 95%CI (0.19-0.78); p = 0.015]. A history of COVID-19 was associated with an optimal response [OR 4.03; 95%CI (2.09-7.79); p < 0.0001], while an older age at vaccination [OR 0.97; 95%CI (0.95-0.99); p = 0.002], less than 36 months between kidney transplantation and vaccination [OR 0.35; 95%CI (0.18-0.69); p = 0.002], a higher creatinine level [OR 0.60; 95%CI (0.38-0.93); p = 0.02], three-drug immunosuppression [OR 0.45; 95%CI (0.27-0.76); p = 0.003] were associated with a poorer response.

Conclusion: We identified factors associated with a humoral response to a COVID-19 mRNA vaccine in KTRs. These findings might help physicians to optimize vaccination in KTRs.

Keywords: COVID-19; Humoral response; Kidney transplantation; SARS-CoV-2; mRNA vaccine.

PubMed Disclaimer

References

    1. Caillard S, Chavarot N, Francois H, et al. Is Covid-19 infection more severe in kidney transplant recipients? Am J Transplant. 2020. https://doi.org/10.1111/ajt.16424 . - DOI - PubMed - PMC
    1. Caillard S, Anglicheau D, Matignon M, et al. An initial report from the French SOT COVID Registry suggests high mortality due to COVID-19 in recipients of kidney transplants. Kidney Int. 2020;98(6):1549–58. https://doi.org/10.1016/j.kint.2020.08.005 . - DOI - PubMed - PMC
    1. The impact of COVID‐19 on kidney transplantation and the kidney transplant recipient—one year into the pandemic—Khairallah. Transplant Int. 2021. Wiley Online Library. https://onlinelibrary.wiley.com/doi/10.1111/tri.13840 . Accessed 30 Jan 2022.
    1. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384(5):403–16. https://doi.org/10.1056/NEJMoa2035389 . - DOI - PubMed
    1. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–15. https://doi.org/10.1056/NEJMoa2034577 . - DOI - PubMed

LinkOut - more resources